-
2
-
-
1542329005
-
The erbB family: Targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitors
-
Rowinsky EK. The erbB family: targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitors. Annu Rev Med 2004;55:433-457.
-
(2004)
Annu Rev Med
, vol.55
, pp. 433-457
-
-
Rowinsky, E.K.1
-
3
-
-
44449127592
-
The epidermal growth factor receptor family: Biology driving targeted therapeutics
-
Wieduwilt MJ, Moasser MM. The epidermal growth factor receptor family: biology driving targeted therapeutics. Cell Mol Life Sci 2008; 65:1566-1584.
-
(2008)
Cell Mol Life Sci
, vol.65
, pp. 1566-1584
-
-
Wieduwilt, M.J.1
Moasser, M.M.2
-
4
-
-
63149108552
-
Mutations and response to epidermal growth factor receptor inhibitors
-
Laurent-Puig P, Lievre A, Blons H. Mutations and response to epidermal growth factor receptor inhibitors. Clin Cancer Res 2009;15:1133-1139.
-
(2009)
Clin Cancer Res
, vol.15
, pp. 1133-1139
-
-
Laurent-Puig, P.1
Lievre, A.2
Blons, H.3
-
5
-
-
2342471392
-
Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall- cell lung cancer to gefitinib
-
Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall- cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139.
-
(2004)
N Engl J Med
, vol.350
, pp. 2129-2139
-
-
Lynch, T.J.1
Bell, D.W.2
Sordella, R.3
-
6
-
-
2342624080
-
EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy
-
Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304: 1497-1500.
-
(2004)
Science
, vol.304
, pp. 1497-1500
-
-
Paez, J.G.1
Janne, P.A.2
Lee, J.C.3
-
7
-
-
15744372810
-
KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib
-
Pao W, Wang TY, Riely GJ, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005;2:e17.
-
(2005)
PLoS Med
, vol.2
-
-
Pao, W.1
Wang, T.Y.2
Riely, G.J.3
-
8
-
-
33646418681
-
Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation
-
Han SW, Kim TY, Jeon YK, et al. Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation. Clin Cancer Res 2006;12:2538-2544.
-
(2006)
Clin Cancer Res
, vol.12
, pp. 2538-2544
-
-
Han, S.W.1
Kim, T.Y.2
Jeon, Y.K.3
-
9
-
-
34249810645
-
KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer
-
Massarelli E, Varella-Garcia M, Tang X, et al. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res 2007;13:2890-2896.
-
(2007)
Clin Cancer Res
, vol.13
, pp. 2890-2896
-
-
Massarelli, E.1
Varella-Garcia, M.2
Tang, X.3
-
10
-
-
24644445676
-
Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients
-
Cappuzzo F, Varella-Garcia M, Shigematsu H, et al. Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients. J Clin Oncol 2005;23:5007-5018.
-
(2005)
J Clin Oncol
, vol.23
, pp. 5007-5018
-
-
Cappuzzo, F.1
Varella-Garcia, M.2
Shigematsu, H.3
-
11
-
-
20144386787
-
Somatic mutations of the HER2 kinase domain in lung adenocarcinomas
-
Shigematsu H, Takahashi T, Nomura M, et al. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res 2005;65: 1642-1646.
-
(2005)
Cancer Res
, vol.65
, pp. 1642-1646
-
-
Shigematsu, H.1
Takahashi, T.2
Nomura, M.3
-
12
-
-
33847091172
-
EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients
-
Bae NC, Chae MH, Lee MH, et al. EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients. Cancer Genet Cytogenet 2007;173:107-113.
-
(2007)
Cancer Genet Cytogenet
, vol.173
, pp. 107-113
-
-
Bae, N.C.1
Chae, M.H.2
Lee, M.H.3
-
13
-
-
48249102662
-
Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients
-
Koivunen JP, Kim J, Lee J, et al. Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients. Br J Cancer 2008;99:245-252.
-
(2008)
Br J Cancer
, vol.99
, pp. 245-252
-
-
Koivunen, J.P.1
Kim, J.2
Lee, J.3
-
14
-
-
77955092315
-
PTEN mutations and relationship to EGFR, ERBB2, KRAS, and TP53 mutations in non-small cell lung cancers
-
Jin G, Kim MJ, Jeon HS, et al. PTEN mutations and relationship to EGFR, ERBB2, KRAS, and TP53 mutations in non-small cell lung cancers. Lung Cancer. 2010;69:279-283.
-
(2010)
Lung Cancer.
, vol.69
, pp. 279-283
-
-
Jin, G.1
Kim, M.J.2
Jeon, H.S.3
-
15
-
-
71649110520
-
LKB1 mutations are extremely rare in Korean non-small cell lung cancers
-
Kim MJ, Jin G, Jheon HS, et al. LKB1 mutations are extremely rare in Korean non-small cell lung cancers. Cancer Genet Cytogenet 2010;196: 204-206.
-
(2010)
Cancer Genet Cytogenet
, vol.196
, pp. 204-206
-
-
Kim, M.J.1
Jin, G.2
Jheon, H.S.3
-
16
-
-
0035691670
-
The new World Health Organization classification of lung tumours
-
Brambilla E, Travis WD, Colby TV, et al. The new World Health Organization classification of lung tumours. Eur Respir J 2001;18: 1059-1068.
-
(2001)
Eur Respir J
, vol.18
, pp. 1059-1068
-
-
Brambilla, E.1
Travis, W.D.2
Colby, T.V.3
-
18
-
-
77955291678
-
TP53 mutations in Korean patients with non-small cell lung cancer
-
Lee EB, Jin G, Lee SY, et al. TP53 mutations in Korean patients with non-small cell lung cancer. J Korean Med Sci 2010;25:698-705.
-
(2010)
J Korean Med Sci
, vol.25
, pp. 698-705
-
-
Lee, E.B.1
Jin, G.2
Lee, S.Y.3
-
20
-
-
66149141021
-
PTEN and the PI3-kinase pathway in cancer
-
Chalhoub N, Baker SJ. PTEN and the PI3-kinase pathway in cancer. Annu Rev Pathol 2009;4:127-150.
-
(2009)
Annu Rev Pathol
, vol.4
, pp. 127-150
-
-
Chalhoub, N.1
Baker, S.J.2
-
21
-
-
33751084640
-
PIK3CA mutation status in Japanese lung cancer patients
-
Kawano O, Sasaki H, Endo K, et al. PIK3CA mutation status in Japanese lung cancer patients. Lung Cancer 2006;54:209-215.
-
(2006)
Lung Cancer
, vol.54
, pp. 209-215
-
-
Kawano, O.1
Sasaki, H.2
Endo, K.3
-
22
-
-
0031596872
-
Inactivation of the PTEN/ MMAC1/TEP1 gene in human lung cancers
-
Kohno T, Takahashi M, Manda R, et al. Inactivation of the PTEN/ MMAC1/TEP1 gene in human lung cancers. Genes Chromosomes Cancer 1998;22:152-156.
-
(1998)
Genes Chromosomes Cancer
, vol.22
, pp. 152-156
-
-
Kohno, T.1
Takahashi, M.2
Manda, R.3
-
23
-
-
52049099853
-
PIK3CA mutations and copy number gains in human lung cancers
-
Yamamoto H, Shigematsu H, Nomura M, et al. PIK3CA mutations and copy number gains in human lung cancers. Cancer Res 2008;68:6913-6921.
-
(2008)
Cancer Res
, vol.68
, pp. 6913-6921
-
-
Yamamoto, H.1
Shigematsu, H.2
Nomura, M.3
-
24
-
-
0036645101
-
Genomic copy number analysis of non-small cell lung cancer using array comparative genomic hybridization: Implications of the phosphatidylinositol 3-kinase pathway
-
Massion PP, Kuo WL, Stokoe D, et al. Genomic copy number analysis of non-small cell lung cancer using array comparative genomic hybridization: implications of the phosphatidylinositol 3-kinase pathway. Cancer Res 2002;62:3636-3640.
-
(2002)
Cancer Res
, vol.62
, pp. 3636-3640
-
-
Massion, P.P.1
Kuo, W.L.2
Stokoe, D.3
-
25
-
-
10844231985
-
Mutations of the epidermal growth factor receptor gene in lung cancer: Biological and clinical implications
-
Kosaka T, Yatabe Y, Endoh H, et al. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 2004;64:8919-8923.
-
(2004)
Cancer Res
, vol.64
, pp. 8919-8923
-
-
Kosaka, T.1
Yatabe, Y.2
Endoh, H.3
-
26
-
-
20044364940
-
Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers
-
Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005;97:339-346.
-
(2005)
J Natl Cancer Inst
, vol.97
, pp. 339-346
-
-
Shigematsu, H.1
Lin, L.2
Takahashi, T.3
-
27
-
-
28844501639
-
Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers
-
Shigematsu H, Gazdar AF. Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer 2006; 118:257-262.
-
(2006)
Int J Cancer
, vol.118
, pp. 257-262
-
-
Shigematsu, H.1
Gazdar, A.F.2
-
28
-
-
84887212361
-
Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines
-
Gandhi J, Zhang J, Xie Y, et al. Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines. PLoS One 2009;4:e4576.
-
(2009)
PLoS One
, vol.4
-
-
Gandhi, J.1
Zhang, J.2
Xie, Y.3
-
29
-
-
65949086609
-
PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR
-
Sos ML, Koker M, Weir BA, et al. PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Res 2009;69:3256-3261.
-
(2009)
Cancer Res
, vol.69
, pp. 3256-3261
-
-
Sos, M.L.1
Koker, M.2
Weir, B.A.3
-
30
-
-
10744227337
-
Loss of heterozygosity of chromosome 12p does not correlate with KRAS mutation in non-small cell lung cancer
-
Uchiyama M, Usami N, Kondo M, et al. Loss of heterozygosity of chromosome 12p does not correlate with KRAS mutation in non-small cell lung cancer. Int J Cancer 2003;107:962-969.
-
(2003)
Int J Cancer
, vol.107
, pp. 962-969
-
-
Uchiyama, M.1
Usami, N.2
Kondo, M.3
-
31
-
-
18444374405
-
Mutations of the BRAF gene in human cancer
-
Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-954.
-
(2002)
Nature
, vol.417
, pp. 949-954
-
-
Davies, H.1
Bignell, G.R.2
Cox, C.3
-
32
-
-
27244457769
-
Raf: A strategic target for therapeutic development against cancer
-
Beeram M, Patnaik A, Rowinsky EK. Raf: a strategic target for therapeutic development against cancer. J Clin Oncol 2005;23:6771-6790.
-
(2005)
J Clin Oncol
, vol.23
, pp. 6771-6790
-
-
Beeram, M.1
Patnaik, A.2
Rowinsky, E.K.3
-
33
-
-
44249125256
-
EGFR tyrosine kinase inhibitors for the treatment of NSCLC in East Asia: Present and future
-
Yang CH. EGFR tyrosine kinase inhibitors for the treatment of NSCLC in East Asia: present and future. Lung Cancer 2008;60(Suppl 2):S23-S30.
-
(2008)
Lung Cancer
, vol.60
, Issue.SUPPL 2
-
-
Yang, C.H.1
-
34
-
-
33847323129
-
Epidermal growth factor receptor mutations in lung cancer
-
Sharma SV, Bell DW, Settleman J, et al. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007;7:169-181.
-
(2007)
Nat Rev Cancer
, vol.7
, pp. 169-181
-
-
Sharma, S.V.1
Bell, D.W.2
Settleman, J.3
-
36
-
-
26444459867
-
Clinicopathologic significance of the mutations of the epidermal growth factor receptor gene in patients with non-small cell lung cancer
-
Tomizawa Y, Iijima H, Sunaga N, et al. Clinicopathologic significance of the mutations of the epidermal growth factor receptor gene in patients with non-small cell lung cancer. Clin Cancer Res 2005;11:6816-6822.
-
(2005)
Clin Cancer Res
, vol.11
, pp. 6816-6822
-
-
Tomizawa, Y.1
Iijima, H.2
Sunaga, N.3
-
37
-
-
11144358645
-
High frequency of mutations of the PIK3CA gene in human cancers
-
Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004;304:554.
-
(2004)
Science
, vol.304
, pp. 554
-
-
Samuels, Y.1
Wang, Z.2
Bardelli, A.3
-
38
-
-
23444461754
-
PTEN expression in non-small- cell lung cancer: Evaluating its relation to tumor characteristics, allelic loss, and epigenetic alteration
-
Marsit CJ, Zheng S, Aldape K, et al. PTEN expression in non-small- cell lung cancer: evaluating its relation to tumor characteristics, allelic loss, and epigenetic alteration. Hum Pathol 2005;36:768-776.
-
(2005)
Hum Pathol
, vol.36
, pp. 768-776
-
-
Marsit, C.J.1
Zheng, S.2
Aldape, K.3
-
39
-
-
0036094196
-
Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation
-
Soria JC, Lee HY, Lee JI, et al. Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation. Clin Cancer Res 2002;8:1178-1184.
-
(2002)
Clin Cancer Res
, vol.8
, pp. 1178-1184
-
-
Soria, J.C.1
Lee, H.Y.2
Lee, J.I.3
-
40
-
-
34748881277
-
LKB1 gene mutations in Japanese lung cancer patients
-
Onozato R, Kosaka T, Achiwa H, et al. LKB1 gene mutations in Japanese lung cancer patients. Cancer Sci 2007;98:1747-1751.
-
(2007)
Cancer Sci
, vol.98
, pp. 1747-1751
-
-
Onozato, R.1
Kosaka, T.2
Achiwa, H.3
-
41
-
-
67749108202
-
A gene-alteration profile of human lung cancer cell lines
-
Blanco R, Iwakawa R, Tang M, et al. A gene-alteration profile of human lung cancer cell lines. Hum Mutat 2009;30:1199-1206.
-
(2009)
Hum Mutat
, vol.30
, pp. 1199-1206
-
-
Blanco, R.1
Iwakawa, R.2
Tang, M.3
-
42
-
-
54549094903
-
Somatic mutations affect key pathways in lung adenocarcinoma
-
Ding L, Getz G, Wheeler DA, et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008;455:1069-1075.
-
(2008)
Nature
, vol.455
, pp. 1069-1075
-
-
Ding, L.1
Getz, G.2
Wheeler, D.A.3
-
43
-
-
33644515295
-
Somatic mutations of the ERBB4 kinase domain in human cancers
-
Soung YH, Lee JW, Kim SY, et al. Somatic mutations of the ERBB4 kinase domain in human cancers. Int J Cancer 2006;118:1426-1429.
-
(2006)
Int J Cancer
, vol.118
, pp. 1426-1429
-
-
Soung, Y.H.1
Lee, J.W.2
Kim, S.Y.3
-
44
-
-
41849132829
-
Activating E17K mutation in the gene encoding the protein kinase AKT1 in a subset of squamous cell carcinoma of the lung
-
Malanga D, Scrima M, De Marco C, et al. Activating E17K mutation in the gene encoding the protein kinase AKT1 in a subset of squamous cell carcinoma of the lung. Cell Cycle 2008;7:665-669.
-
(2008)
Cell Cycle
, vol.7
, pp. 665-669
-
-
Malanga, D.1
Scrima, M.2
De Marco, C.3
-
45
-
-
0028071555
-
Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis
-
Greenblatt MS, Bennett WP, Hollstein M, et al. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994;54:4855-4878.
-
(1994)
Cancer Res
, vol.54
, pp. 4855-4878
-
-
Greenblatt, M.S.1
Bennett, W.P.2
Hollstein, M.3
|